Federal Minister for national health services, regulations and coordination Syed Mustafa Kamal on Saturday stated that Pakistan offered significant investment opportunities in the pharmaceutical sector, urging Chinese companies to strengthen partnerships with Pakistani firms through the B2B investment platform.
He said these views while addressing the “Pakistan-China B2B Investment Conference 2026”, adding that Pakistan’s geographical location and investment environment offered attractive opportunities for investors.
The Minister underscored that the pharmaceutical industry was directly linked to public health and would continue to remain a priority sector for the country.
He said that the investment in Pakistan’s pharmaceutical industry would provide access not only to the domestic market but also to regional and international markets.
Kamal expressed confidence that the Drug Regulatory Authority of Pakistan (DRAP) would achieve the WHO Maturity Level 3 (ML3) accreditation by April 2027 after completing the required regulatory benchmarks.
He said the milestone would significantly enhance Pakistan’s pharmaceutical regulatory system, enabling the country to export pharmaceutical products to more than 100 additional international markets.
Referring to the memorandums of understanding (MoUs) and agreements signed during the conference, Mustafa Kamal said the government’s priority was to ensure their effective implementation.
The minister assured local and Chinese investors that the government and the Ministry of National Health Services would provide all possible facilitation, like cutting red tape, to help investment projects materialise.
Concluding his address, Kamal thanked the Chinese delegates for participating in the conference and expressed confidence that the two-day event would further strengthen Pakistan-China cooperation in the pharmaceutical sector and open new avenues for trade and investment.
